Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

Summary

This is a validation study that will replicate a completed study designed to assess biomarkers of treatment response to standard antidepressant treatment. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).

Conditions

• Major Depressive Disorder

Interventions

DRUG

Escitalopram

Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.

DRUG

Brexpiprazole

Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.

Sponsors & Collaborators

• Unity Health Toronto

  collaborator OTHER

• Baycrest

  collaborator OTHER

• Centre for Addiction and Mental Health

  collaborator OTHER

• McMaster University

  collaborator OTHER

• Queen's University

  collaborator OTHER

• University of Ottawa

  collaborator OTHER

• University of British Columbia

  collaborator OTHER

• University of Calgary

  collaborator OTHER

• McGill University

  collaborator OTHER

• Dalhousie University

  collaborator OTHER

• University of Michigan

  collaborator OTHER

• Simon Fraser University

  collaborator OTHER

• University Health Network, Toronto

  lead OTHER

Principal Investigators

• Sidney H Kennedy, MD · University Health Network, St. Michael's University, University of Toronto

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

FACTORIAL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-12-23

Primary Completion

2022-12-31

Completion

2022-12-31

Countries

• Canada

Study Locations